Objective： To determine the short term efficacy and safety of different intensive anti-platelet treatments for patients who received percutaneous coronary intervention(PCI), but presented clopidogrel low response(CLR). Methods: The light transmittance aggregometer(LTA) was adopted to screen patients, who underwent PCI and presented CLR, and 150 clopidogrel low responders were consecutively recruited during their hospitalization. The included patients were randomized and assigned into three groups: ①the regular treatment group (Group A): taking aspirin 100 mg daily and clopidogrel 75 mg daily for one year; ②the intensive treatment group (Group B) : taking aspirin 100 mg daily and clopidogrel 150 mg daily for one month and then switched to regular anti-platelet treatment as group A for one year; ③the intensive treatment group (Group C): taking aspirin 100 mg daily and ticagrelor 90 mg twice daily for one month then turned to regular anti-platelet treatment as group A for one year. All recruited patients were followed up at one month after randomization, when the adenosine diphosphate induced platelet aggregation(PLADP) and arachidonic acid induced platelet aggregation(PLAA) was determined and clinical events were recorded. Results: There were no significant differences regarding the baseline clinical data and biochemical indexes among Groups A, B, and C, so were the baseline levels of PLADP（P=0.553）, and the baseline levels of PLAA（P=0.352）. At one month follow-up, the PLADP in Group B and Group C were both significantly lower than their baseline levels (P<0.001); and the PLADP level in Group C was significantly lower than that in Groups A and B; the PLAA levels of Groups A, B and C had no significant differences among the groups. The total incidences of in-stent thrombus, target vessel revascularization and cardiogenic hospitalization at 1 month were 20%, 10% and 4% in Group A, B and C, respectively(P=0.039). The incidences of minimal bleeding at 1 month were 10%, 14% and 8%, respectively in the three groups (P=0.044). The incidence of dyspnea in Group C was 6%, which was significantly higher compared to the other two groups(P=0.01). Conclusion: Double-dose clopidogrel or ticagrelor can effectively reduce the residual platelet aggregation for CLR patients; Ticagrelor can otherwise bring down the total incidences of in-stent thrombus, target vessel revascularization and cardiogenic hospitalization one month after the procedure, at the risk of increased dyspnea and minimal bleeding.